6,6-Fused Heteroaryl Piperidine Ether M4 Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current muscarinic agonists for treating Alzheimer's disease and schizophrenia face challenges due to lack of receptor subtype selectivity, leading to dose-limiting side effects such as gastrointestinal disturbances and cardiovascular issues.
Innovation Solution
Development of 6,6-fused heteroarylpiperidine ether compounds as selective allosteric modulators of the M4 muscarinic acetylcholine receptor to modulate M4 muscarinic acetylcholine receptor activity, potentially offering improved therapeutic efficacy with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective muscarinic agonists are used to treat Alzheimer's disease and schizophrenia, then cognitive and psychiatric symptoms are improved, but dose-limiting side effects occur due to lack of receptor subtype selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (6,6-fused heteroaryl piperidine ether framework) that confer selective affinity for the M4 muscarinic receptor subtype. This structural optimization enables the compound to interact preferentially with M4 receptors in the striatum while minimizing interaction with other muscarinic subtypes, thereby achieving localized therapeutic effect with reduced side effects
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters such as heteroaryl substituents, piperidine ring configurations, and ether linkage positions to optimize M4 receptor selectivity. These parameter optimizations adjust the compound's binding characteristics to achieve high affinity and selectivity for M4 receptors, resolving the contradiction between therapeutic efficacy and side effect profile
2Ease of operation
If muscarinic agonists are administered to activate mAChRs, then pro-cognitive and antipsychotic effects are achieved, but gastrointestinal motility disturbances and cardiovascular side effects occur
Solution Approach 1:
The patent applies segmentation by focusing therapeutic action on a specific receptor subtype (M4) rather than activating all muscarinic receptors nonselectively. The M4 receptor is predominantly expressed in the striatum and involved in cognitive and psychiatric functions, while having minimal distribution in gastrointestinal and cardiovascular tissues. This selective activation segments the therapeutic effect from harmful side effects
Solution Approach 2:
The patent uses the M4 muscarinic receptor as an intermediary target to achieve cognitive and psychiatric benefits. By designing compounds that selectively activate M4 receptors, the therapy mediates therapeutic effects through this specific receptor pathway while avoiding activation of other muscarinic subtypes that would cause gastrointestinal and cardiovascular side effects
Data Source
AI summary
The present invention is directed to 6,6-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.